Trials / Completed
CompletedNCT00897637
Gene Expression Profiles to Categorize Wilms Tumors
Categorization of Wilms Tumors by Genetic Expression
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 600 (actual)
- Sponsor
- Children's Oncology Group · Network
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This laboratory study is using gene expression profiling to identify different categories of Wilms tumors. Studying the genes expressed in samples of tumor tissue from patients with cancer may help doctors identify biomarkers related to cancer.
Detailed description
OBJECTIVES: I. Identify new molecular categories of Wilms tumor (WT) based on the gene expression profiles of samples from patients with this disease. II. Develop a classifying system (classifier) that will predict a defined number of clinically relevant categories based on expression of an established set of genes. III. Confirm and test the classifier with further analysis of the genes by several different methodologies, using additional patient samples that are outside of the case/cohort but which possess the clinically or scientifically relevant parameter. IV. Validate the use of the classifier to predict defined groups within a second set of samples (for which investigators are blinded to the clinical and biological data) by subsequent comparison with true incidence of pertinent markers. OUTLINE: Three hundred tumor specimens are analyzed for genetic expression profiles using Affymetrix assays. Specific genes are identified as classifiers and analyzed using tissue arrays. An additional 300 specimens are examined for gene expression and categorized according to the classifiers.
Conditions
- Recurrent Wilms Tumor and Other Childhood Kidney Tumors
- Stage I Wilms Tumor
- Stage II Wilms Tumor
- Stage III Wilms Tumor
- Stage IV Wilms Tumor
- Stage V Wilms Tumor
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | laboratory biomarker analysis | Correlative studies |
Timeline
- Start date
- 2004-02-01
- Primary completion
- 2016-05-01
- First posted
- 2009-05-12
- Last updated
- 2016-05-19
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00897637. Inclusion in this directory is not an endorsement.